Align Technology’s (ALGN) Buy Rating Reaffirmed at Northcoast Research

Align Technology, Inc. (NASDAQ:ALGN)‘s stock had its “buy” rating reissued by stock analysts at Northcoast Research in a note issued to investors on Tuesday. They presently have a $230.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $200.00. Northcoast Research’s price target indicates a potential upside of 22.26% from the stock’s previous close.

ALGN has been the subject of several other research reports. Zacks Investment Research lowered Align Technology from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 21st. Morgan Stanley reissued an “overweight” rating and set a $220.00 price objective (up previously from $195.00) on shares of Align Technology in a research note on Friday. Leerink Swann lifted their price objective on Align Technology from $149.00 to $194.00 and gave the company an “outperform” rating in a research note on Monday, June 26th. Goldman Sachs Group, Inc. (The) lifted their price objective on Align Technology from $185.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Finally, Robert W. Baird reissued a “buy” rating on shares of Align Technology in a research note on Tuesday, September 12th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Align Technology has an average rating of “Buy” and an average target price of $193.20.

Align Technology (NASDAQ ALGN) traded up 0.36% during mid-day trading on Tuesday, hitting $188.81. The stock had a trading volume of 484,615 shares. The firm’s 50-day moving average is $181.76 and its 200 day moving average is $153.16. Align Technology has a 12 month low of $83.27 and a 12 month high of $191.78. The company has a market cap of $15.13 billion, a price-to-earnings ratio of 64.66 and a beta of 1.54.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.12. The company had revenue of $356.50 million during the quarter, compared to analyst estimates of $343.43 million. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The firm’s quarterly revenue was up 32.3% on a year-over-year basis. During the same quarter last year, the company earned $0.62 earnings per share. Equities analysts anticipate that Align Technology will post $3.41 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Align Technology’s (ALGN) Buy Rating Reaffirmed at Northcoast Research” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.themarketsdaily.com/2017/10/10/align-technologys-algn-buy-rating-reaffirmed-at-northcoast-research.html.

A number of hedge funds have recently modified their holdings of the business. Navellier & Associates Inc lifted its stake in Align Technology by 4.5% during the second quarter. Navellier & Associates Inc now owns 68,761 shares of the medical equipment provider’s stock worth $10,322,000 after purchasing an additional 2,963 shares during the last quarter. Sentry Investment Management LLC bought a new stake in Align Technology during the second quarter worth about $882,000. Ashford Capital Management Inc. lifted its stake in Align Technology by 46.9% during the second quarter. Ashford Capital Management Inc. now owns 6,941 shares of the medical equipment provider’s stock worth $1,042,000 after purchasing an additional 2,216 shares during the last quarter. Toronto Dominion Bank lifted its stake in Align Technology by 3,163.1% during the second quarter. Toronto Dominion Bank now owns 25,583 shares of the medical equipment provider’s stock worth $3,840,000 after purchasing an additional 24,799 shares during the last quarter. Finally, Cetera Investment Advisers bought a new stake in Align Technology during the second quarter worth about $470,000. 81.56% of the stock is owned by hedge funds and other institutional investors.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply